Sam Brusco, Associate Editor02.28.24
Glucotrack announced that is has chosen Cirtec Medical as manufacturer for the implantable Continuous Blood Glucose Monitor (CBGM). The two companies signed a deal for clinical and commercial manufacturing.
The CBGM is a long-term, implantable system that measures blood glucose levels with a sensor lifetime of two or more years, no on-body wearable component, and a once-only calibration event. GlucoTrack recently announced it had finished its first preclinical study in animals.
“Cirtec is a leader in the design and manufacturing of implantable medical devices in the fields of neuromodulation, cardiology and drug delivery. They are a natural fit to be the manufacturer of our CBGM, which leverages their deep experience in implantable technologies and brings it to the diabetes market,” said Paul Goode, Ph.D., CEO of Glucotrack. “Their expertise has already contributed extensively to our product design process, and we expect this relationship to accelerate the pace at which this technology becomes available for human clinical trials and then scalable for commercialization.”
Cirtec Medical is a full-service outsource partner that offers product design, development, and manufacturing services to medical device OEMs. The company has over three decades of experience in the product development lifecycle for complex medical devices.
The duo will collaborate to finish development and manufacturing activities to support the implantable CBGM’s first-in-human studies, which are anticipated later this year.
“Cirtec is proud to work with Glucotrack, further cementing our expanding role into implantable devices in the diabetes market,” stated Brian Highley, Cirtec CEO. “Our agreement capitalizes on Cirtec’s extensive expertise in implantable medical device design, development, and manufacturing and Glucotrack's innovation in CBGM. Together, we are committed to advancing technology solutions for people living with diabetes worldwide.”
The CBGM is a long-term, implantable system that measures blood glucose levels with a sensor lifetime of two or more years, no on-body wearable component, and a once-only calibration event. GlucoTrack recently announced it had finished its first preclinical study in animals.
“Cirtec is a leader in the design and manufacturing of implantable medical devices in the fields of neuromodulation, cardiology and drug delivery. They are a natural fit to be the manufacturer of our CBGM, which leverages their deep experience in implantable technologies and brings it to the diabetes market,” said Paul Goode, Ph.D., CEO of Glucotrack. “Their expertise has already contributed extensively to our product design process, and we expect this relationship to accelerate the pace at which this technology becomes available for human clinical trials and then scalable for commercialization.”
Cirtec Medical is a full-service outsource partner that offers product design, development, and manufacturing services to medical device OEMs. The company has over three decades of experience in the product development lifecycle for complex medical devices.
The duo will collaborate to finish development and manufacturing activities to support the implantable CBGM’s first-in-human studies, which are anticipated later this year.
“Cirtec is proud to work with Glucotrack, further cementing our expanding role into implantable devices in the diabetes market,” stated Brian Highley, Cirtec CEO. “Our agreement capitalizes on Cirtec’s extensive expertise in implantable medical device design, development, and manufacturing and Glucotrack's innovation in CBGM. Together, we are committed to advancing technology solutions for people living with diabetes worldwide.”